Who Owns Harrow Company?

Harrow Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Harrow Company?

Understanding the ownership of a company is paramount for investors and strategists alike. A company's ownership structure dictates its strategic decisions, influencing everything from product development to market expansion. Discovering who owns Harrow Company is crucial for anyone seeking to understand the trajectory of this key player in the ophthalmic pharmaceutical sector.

Harrow, Inc., a company with a rich history dating back to 2006, has evolved significantly. From its initial focus to its current market position, understanding the Harrow SWOT Analysis is a key step in understanding its evolution. This exploration will unravel the Harrow Company ownership structure, from its founders and early financial backers to its current major investors and public shareholders, offering insights into the forces shaping its future. Learn about the Harrow Company history, Harrow Company management, and the key Harrow Company executives.

Understanding the ownership structure of the company is crucial for investors and stakeholders alike. The story of the company begins with its incorporation in 2006, but its operational journey in pharmaceuticals commenced in December 2011.

The company's inception and early direction were spearheaded by Mark L. Baum. He holds the positions of Founder, Chairman of the Board, and Chief Executive Officer, playing a pivotal role in shaping the company's initial strategy and vision.

While the specific equity distribution among the founders at the company's outset isn't publicly available, the company's early strategic moves and investments laid the groundwork for its future in the pharmaceutical industry. The company's history is detailed in Brief History of Harrow.

Founding

The company's journey in the pharmaceutical space started in December 2011. Mark L. Baum is recognized as the Founder, Chairman of the Board, and Chief Executive Officer.

Early Revenue

The company began generating revenue in April 2014 through its ImprimisRx brand. Its initial product was a compounded intraocular injectable steroid and antibiotic.

Subsidiaries and Investments

Harrow Health, Inc. (former name) owned royalty rights in drug candidates developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. Both companies started as Harrow subsidiaries.

Current Equity Stakes (as of February 2025)

Harrow retains a 20% equity stake in Surface Ophthalmics. It also holds an approximately 46% equity ownership in Melt Pharmaceuticals.

Key Takeaways on Harrow Company Ownership

The company's ownership structure is shaped by its founder and early strategic investments. The company's investments in subsidiaries like Surface Ophthalmics and Melt Pharmaceuticals demonstrate its strategy. As of February 2025, the company maintains significant equity stakes in these subsidiaries, reflecting its ongoing involvement and interest in their development.

• Mark L. Baum is the Founder, Chairman, and CEO.
• Early investments in Surface Ophthalmics and Melt Pharmaceuticals.
• The company holds a 20% stake in Surface Ophthalmics.
• The company owns approximately 46% of Melt Pharmaceuticals as of February 2025.

Harrow SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of Harrow Company ownership has been shaped by key events, including public offerings and strategic acquisitions. Initially known as Imprimis Pharmaceuticals, Inc., the company went public on September 27, 2007. A significant event was the underwritten registered public offering in July 2023, where 3,380,282 shares were offered at $17.75 per share, generating $60 million in gross proceeds. These funds were allocated for acquisitions and general corporate purposes. This offering and others have helped fund the acquisition of ophthalmic products, such as the acquisition of five FDA-approved products, including TRIESENCE, in early 2023.

The ownership structure of Harrow is a mix of institutional, retail, and individual investors. As of June 11, 2025, the share price was $31.61, reflecting a 73.21% increase from $18.25 on June 12, 2024. Institutional investors hold a significant portion of the shares, with 57.62% as of May 2025, while insiders hold 15.27%. Retail investors account for approximately 29.00% of the stock. The company has 324 institutional owners, holding a total of 23,334,939 shares.

Major institutional shareholders include Opaleye Management Inc., which holds the most shares. Other significant investors include BlackRock, Inc., and Vanguard Group Inc. Mutual funds slightly decreased their holdings from 31.42% to 31.31% in May 2025. These changes in ownership reflect the ongoing investment and strategic direction of the company, particularly in acquiring and commercializing ophthalmic products.

Ownership Dynamics of Harrow Company

Harrow Company's ownership structure is diverse, with institutional investors holding the majority of shares. The share price has increased significantly, reflecting positive investor sentiment. Key events, such as public offerings and acquisitions, have shaped the company's ownership landscape.

• Institutional investors hold a significant portion of shares.
• Retail investors also play a role in the ownership structure.
• Strategic acquisitions have influenced ownership dynamics.
• The company's stock price has shown positive growth.

Harrow PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of the latest information, the Board of Directors of Harrow, Inc. comprises six directors. The governance structure is defined by the company's Amended and Restated Bylaws, which were last updated on September 29, 2023. Mark L. Baum holds the dual roles of Chief Executive Officer and Chairman of the Board.

The proxy statement for the 2024 Annual Meeting of Stockholders, held on June 14, 2024, identified five director nominees for election, each to serve until the 2025 Annual Meeting. This structure ensures a continuous oversight and strategic direction for the company. Understanding the Revenue Streams & Business Model of Harrow can provide additional context to the board's strategic decisions.

The voting rights for Harrow's common stock follow a one-share-one-vote structure. This means that each share of common stock entitles its holder to one vote on all matters brought to a stockholder vote, including the election of directors. As of April 16, 2024, the record date for the 2024 Annual Meeting, there were 35,381,611 shares of common stock outstanding and eligible to vote, held by 67 stockholders of record. Preferred stock, such as Harrow Inc. 11.875% Preferred Stock (HROWM), typically does not carry voting rights similar to common shares. Abstentions and broker non-votes do not directly affect proposal outcomes.

Key Takeaways on Harrow Company Ownership

The Board of Directors consists of six members, with Mark L. Baum as CEO and Chairman. The voting structure is one-share-one-vote for common stock holders.

• The 2024 Annual Meeting had five director nominees.
• As of April 16, 2024, there were 35,381,611 shares outstanding.
• Preferred stock typically does not convey voting rights.
• Institutional investors like LGIM advocate for one-share-one-vote.

Harrow Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the focus of the company has been on strategic acquisitions to bolster its ophthalmic product offerings. Key acquisitions include IHEEZO, launched in May 2023, VEVYE, launched in January 2024, and TRIESENCE, relaunched in late 2024. These moves have been instrumental in shaping the company's growth and market position. The company's financial performance reflects these strategic initiatives.

Financially, the company has seen substantial growth. In Q4 2024, revenues reached a record $66.8 million, representing an 84% increase compared to Q4 2023. Full-year 2024 revenues were $199.6 million, a 53% increase over the previous year. The positive trend continued into Q1 2025, with revenues of $47.8 million, marking a 38% year-over-year increase. The company projects that 2025 revenue will exceed $280 million, mainly driven by its higher-margin branded business. This growth trajectory is significant for understanding the company's current position and future potential.

Regarding Harrow Company ownership, institutional ownership remains a significant factor. As of May 2025, 324 institutional owners held over 23.3 million shares. While institutional holdings were stable at 57.62% in May 2025, mutual fund holdings slightly decreased. Insider holdings remained unchanged at 15.27% in May 2025. A key development was Opaleye Management Inc., a major shareholder, selling over 30,000 shares in June 2025. The company has also utilized public offerings, such as the $60 million offering in July 2023, to fund acquisitions and general corporate purposes. There has been no meaningful dilution of shares for shareholders in the past year. For more details on the company's background, you can check out an article that provides a detailed Harrow Company history.

Institutional Ownership

As of May 2025, institutional owners held over 23.3 million shares.

Insider Holdings

Insider holdings remained unchanged at 15.27% in May 2025.

Recent Transactions

Opaleye Management Inc., a major shareholder, sold over 30,000 shares in June 2025.

Shareholder Dilution

There has been no significant dilution of shares in the past year.

Harrow Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs